Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Receive Gastrectomy and Adjuvant S-1

被引:12
|
作者
Hatori, Shinsuke [1 ,2 ]
Sakamaki, Kentaro [3 ]
Yokohori, Takehiko [4 ]
Kimura, Yayoi [5 ]
Hiroshima, Yukihiko [6 ]
Hashimoto, Itaru [1 ]
Komori, Keisuke [1 ]
Watanabe, Hayato [1 ]
Kano, Kazuki [1 ]
Fujikawa, Hirohito [1 ]
Aoyama, Toru [2 ]
Numata, Masakatsu [2 ]
Yamada, Takanobu [1 ]
Tamagawa, Hiroshi [2 ]
Yamamoto, Naoto [1 ]
Ogata, Takashi [1 ]
Shizawa, Manabu [1 ]
Yukawa, Norio [2 ]
Morinaga, Soichiro [2 ]
Rino, Yasushi [2 ]
Masuda, Munetaka [2 ]
Saeki, Hiroshi [4 ]
Miyagi, Yohei [6 ]
Oshima, Takashi [1 ]
机构
[1] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, 2-3-2 Nakano Asahi, Yokohama, Kanagawa 2418515, Japan
[2] Yokohama City Univ, Dept Surg, Yokohama, Kanagawa, Japan
[3] Yokohama City Univ, Dept Data Sci, Yokohama, Kanagawa, Japan
[4] Gunma Univ, Dept Gastroenterol Surg, Maebashi, Gumma, Japan
[5] Yokohama City Univ, Advanced Med Res Ctr, Yokohama, Kanagawa, Japan
[6] Kanagawa Canc Ctr Res Inst, Yokohama, Kanagawa, Japan
关键词
Gastric cancer; S-1; prognostic factor; PLA2G2A; GROUP IIA PHOSPHOLIPASE-A2; OPEN-LABEL; STAGE-II; CHEMOTHERAPY; CAPECITABINE; OXALIPLATIN; SURVIVAL;
D O I
10.21873/anticanres.15146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to evaluate the prognostic significance of PLA2G2A expression in patients with locally advanced gastric cancer (GC). Patients and Methods: PLA2G2A expression levels in cancerous tissue specimens and adjacent normal mucosa obtained from 134 patients with stage II/III GC who received adjuvant chemotherapy with S-1 after curative resection were measured using real-time quantitative polymerase chain reaction. Subsequently, the associations of PLA2G2A expression with clinicopathological features and survival were evaluated. Results: No association was observed between clinicopathological features and PLA2G2A expression levels. Overall survival was significantly longer in patients with high PLA2G2A expression levels (p=0.022). Multivariate analysis revealed that PLA2G2A expression was a significant, independent prognostic factor (hazard ratio=0.136; 95% confidence interval=0.0185-0.992; p=0.049). Conclusion: PLA2G2A mRNA expression may serve as a useful prognostic marker in patients with locally advanced GC who receive curative surgery and adjuvant chemotherapy with S-1.
引用
收藏
页码:3583 / 3588
页数:6
相关论文
共 50 条
  • [31] Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy
    Tamura, Shigeyuki
    Fujitani, Kazumasa
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    ONCOLOGY, 2011, 80 (5-6) : 296 - 300
  • [32] Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients
    Aoyama, Toru
    Yoshikawa, Takaki
    Watanabe, Takafumi
    Hayashi, Tsutomu
    Ogata, Takashi
    Cho, Haruhiko
    Tsuburaya, Akira
    GASTRIC CANCER, 2012, 15 (01) : 76 - 82
  • [33] Impact of the ESM-1 Gene Expression on Outcomes in Stage II/III Gastric Cancer Patients Who Received Adjuvant S-1 Chemotherapy
    Kano, Kazuki
    Sakamaki, Kentaro
    Oue, Naohide
    Kimura, Yayoi
    Hashimoto, Itaru
    Hara, Kentaro
    Maezawa, Yukio
    Aoyama, Toru
    Fujikawa, Hirohito
    Hiroshima, Yukihiko
    Yamada, Takanobu
    Tamagawa, Hiroshi
    Yamamoto, Naoto
    Ogata, Takashi
    Cho, Haruhiko
    Ito, Hiroyuki
    Shiozawa, Manabu
    Yukawa, Norio
    Yoshikawa, Takaki
    Morinaga, Soichiro
    Rino, Yasushi
    Yasui, Wataru
    Masuda, Munetaka
    Miyagi, Yohei
    Oshima, Takashi
    IN VIVO, 2020, 34 (01): : 461 - 467
  • [34] Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients
    Toru Aoyama
    Takaki Yoshikawa
    Takafumi Watanabe
    Tsutomu Hayashi
    Takashi Ogata
    Haruhiko Cho
    Akira Tsuburaya
    Gastric Cancer, 2012, 15 : 76 - 82
  • [35] Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
    Yoshiaki Nakamura
    Takeharu Yamanaka
    Keisho Chin
    Haruhiko Cho
    Hitoshi Katai
    Masanori Terashima
    Kazunari Misawa
    Motohiro Hirao
    Kazuhiro Yoshida
    Eiji Oki
    Mitsuru Sasako
    Yasunori Emi
    Hideaki Bando
    Yoshiyuki Kawashima
    Tetsu Fukunaga
    Masahiro Gotoh
    Takako Ishibashi
    Kohei Shitara
    Annals of Surgical Oncology, 2019, 26 : 465 - 472
  • [36] Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Chin, Keisho
    Cho, Haruhiko
    Katai, Hitoshi
    Terashima, Masanori
    Misawa, Kazunari
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Bando, Hideaki
    Kawashima, Yoshiyuki
    Fukunaga, Tetsu
    Gotoh, Masahiro
    Ishibashi, Takako
    Shitara, Kohei
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 465 - 472
  • [37] Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients
    Mitsugu Kochi
    Masashi Fujii
    Noriaki Kanamori
    Teruo Kaiga
    Kazuo Aizaki
    Toru Takahashi
    Tadatoshi Takayama
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 693 - 701
  • [38] Phase 1/2 Clinical Study of Irinotecan and Oral S-1 (IRIS) in Patients with Advanced Gastric Cancer
    Komatsu, Yoshito
    Yuki, Satoshi
    Fuse, Nozomu
    Kato, Takashi
    Miyagishima, Takuto
    Kudo, Mineo
    Kunieda, Yasuyuki
    Tateyama, Miki
    Wakahama, Osamu
    Meguro, Takashi
    Sakata, Yuh
    Asaka, Masahiro
    ADVANCES IN THERAPY, 2010, 27 (07) : 483 - 492
  • [39] Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer
    Yoshito Komatsu
    Satoshi Yuki
    Nozomu Fuse
    Takashi Kato
    Takuto Miyagishima
    Mineo Kudo
    Yasuyuki Kunieda
    Miki Tateyama
    Osamu Wakahama
    Takashi Meguro
    Yuh Sakata
    Masahiro Asaka
    Advances in Therapy, 2010, 27 : 483 - 492
  • [40] Predictive factors of outcome and clinical management of adjuvant S-1 chemotherapy for gastric cancer
    Iwasa, S.
    Yamada, Y.
    Nakajima, T. E.
    Kato, K.
    Hamaguchi, T.
    Morita, S.
    Saka, M.
    Fukagawa, T.
    Katai, H.
    Shimada, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)